Cell therapy (TCR-T) · Kills target cells, directed at HA-2 minor histocompatibility antigen · developed by TScan Therapeutics
TSC-101 is a preparation of donor-derived T-lymphocytes engineered to express a T-cell receptor specific for the HLA-A*02:01-restricted minor histocompatibility antigen HA-2. The cells recognize HA-2 on tumor cells and mediate cytotoxic T-lymphocyte elimination of them. It is studied in acute myeloid leukemia and myelodysplastic syndromes after haploidentical hematopoietic cell transplantation.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07702578 | Phase 3 | AML | Active not recruiting | TCRX |
| NCT05473910 | Phase 1 | AML | Active not recruiting | TCRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AMLMDS
See TCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TCRX catalysts and pipeline →